Statin wars: have we been misled about the evidence? A narrative review
Level 5 - mechanism / opinion, no new human data
Narrative review and expert commentary without systematic search methodology or new empirical data.
OpenAlex W2785296722 · doi:10.1136/bjsports-2017-098497
What was done
The authors conducted a narrative review addressing the dispute over prescribing statins to healthy individuals at low risk of cardiovascular disease, focusing on data transparency, potential exaggeration of benefits, and underreporting of adverse events.
What was found
The abstract reports no empirical clinical numbers, effect sizes, or quantitative trial results. It notes commercial projections (global statin sales reaching an estimated US$1 trillion by 2020) and asserts qualitatively that withholding raw trial data prevents independent verification of efficacy and safety.
Why it matters
The paper calls attention to data transparency and open science issues in cardiovascular medicine, arguing for the release of participant-level trial data to establish unbiased benefit-to-harm ratios.
Limits
This is an unsystematic narrative commentary rather than a systematic review or meta-analysis. The abstract presents no original patient data, formal quality appraisal of cited trials, or quantitative measures of statin outcomes.
Cited by
- supports Statins have generated an estimated $1 trillion in global cumulative sales, and the US statin market alone was valued at $4.5 billion in 2023.